{
    "clinical_study": {
        "@rank": "107557", 
        "arm_group": [
            {
                "arm_group_label": "diabetes, vitamin D", 
                "arm_group_type": "Active Comparator", 
                "description": "patients with type 2 diabetes who receive 4000 IU/day vitamin D"
            }, 
            {
                "arm_group_label": "placebo, diabetes", 
                "arm_group_type": "Placebo Comparator", 
                "description": "patients with type 2 diabetes who receive one tab placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is the comparision between the effects of vitamin D or placebo\n      supplementation for 2 months in serum level of thioredoxin, TBP-2 and thioredoxin reductase\n      activity in patients with type 2 diabetes"
        }, 
        "brief_title": "the Effect of Vitamin D on the Serum Thioredoxin, TBP-2, Thioredoxin Reductase, Gene Expression of TBP-2 in Patients With Type II Diabetes", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        literate, willingness to participation, diabetic patients 30- 60 years old, body mass\n        index in the range 18.5- 35, avoidance of dietary supplements, vitamins and herbal\n        products at least 3 months before and throughout the intervention -\n\n        Exclusion Criteria:\n\n        people who have used vitamin D supplements in last 3 months, having chronic renal disease\n        , GI disease, Hepatobilliary diseases, hematological disorders, hypo- or hyperthyroidism,\n        treatment with orlistat or sibutramine for weight loss, pregnancy and lactation, treatment\n        with insulin or Thiazolidinediones, Smokers\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01876563", 
            "org_study_id": "17112"
        }, 
        "intervention": [
            {
                "arm_group_label": "diabetes, vitamin D", 
                "description": "one tab 4000 IU/day vitamin D", 
                "intervention_name": "vitamin D", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "placebo, diabetes", 
                "description": "one tab per day placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "thioredoxin", 
            "TBP-2", 
            "thioredoxin reductase", 
            "vitamin D", 
            "DIABETES"
        ], 
        "lastchanged_date": "June 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of"
                }, 
                "name": "Tehran University of Medical Sciences"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "serum total cholesterol", 
                "safety_issue": "No", 
                "time_frame": "change from baseline at 2 months"
            }, 
            {
                "measure": "serum HDL cholesterol", 
                "safety_issue": "No", 
                "time_frame": "change from baseline at 2 months"
            }, 
            {
                "measure": "serum triglycerides level", 
                "safety_issue": "No", 
                "time_frame": "change from baseline at 2 months"
            }, 
            {
                "measure": "fasting plasma glucose", 
                "safety_issue": "No", 
                "time_frame": "change from baseline at 2 months"
            }, 
            {
                "measure": "serum LDL cholesterol", 
                "safety_issue": "No", 
                "time_frame": "change from baseline at 2 months"
            }, 
            {
                "measure": "complete blood count (CBC)", 
                "safety_issue": "No", 
                "time_frame": "change from baseline at 2 months"
            }, 
            {
                "measure": "HbA1c", 
                "safety_issue": "No", 
                "time_frame": "change from baseline at 2 months"
            }, 
            {
                "measure": "serum insulin", 
                "safety_issue": "No", 
                "time_frame": "change from baseline at 2 months"
            }, 
            {
                "measure": "serum calcidiol", 
                "safety_issue": "No", 
                "time_frame": "change from baseline at 2 months"
            }, 
            {
                "measure": "thioredoxin", 
                "safety_issue": "No", 
                "time_frame": "change from baseline at 2 months"
            }, 
            {
                "measure": "thioredoxin binding protein 2 (TBP-2)", 
                "safety_issue": "No", 
                "time_frame": "change from baseline at 2 months"
            }, 
            {
                "measure": "erytrocyte thioredoxin reductase", 
                "safety_issue": "No", 
                "time_frame": "change from baseline at 2 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01876563"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "GENE EXPRESSION OF TBP-2", 
            "safety_issue": "No", 
            "time_frame": "change from baseline at 2 months"
        }, 
        "source": "Tehran University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tehran University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}